Form 4: United Therapeutics EVP Exercises Options, Sells Shares

Paul A. Mahon, EVP & General Counsel of United Therapeutics, exercised stock options and sold 11,000 shares under a pre-arranged 10b5-1 plan.

Summary

• Paul A. Mahon, Executive Vice President and General Counsel of United Therapeutics Corporation (UTHR), reported a change in beneficial ownership.
• On October 30, 2025, Mahon exercised 11,000 stock options at an exercise price of $135.42 per share.
• Concurrently, Mahon sold all 11,000 shares acquired from the option exercise in multiple transactions.
• The sales occurred at weighted average prices ranging from $447.3438 to $454.1471 per share.
• These transactions were executed pursuant to a pre-arranged Rule 10b5-1 plan, which was entered into on December 24, 2024.
• Following these transactions, Mahon directly owns 36,781 shares of common stock and 11,000 derivative securities (stock options).

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction (exercise of options and sale of shares) executed under a pre-arranged 10b5-1 plan. This is generally considered a neutral event, reflecting personal financial planning rather than a change in the company's operational or financial outlook.

Positives

• The reporting person realized a significant gain by exercising options at $135.42 and selling shares at an average price well over $447.
• The transaction was conducted under a pre-arranged 10b5-1 plan, indicating a planned personal financial management strategy rather than a reaction to new company-specific news.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by some market participants, though it is a routine event for executives managing their equity compensation.

Risks

• No specific company-related risks are detailed in this Form 4 filing, which primarily reports an insider transaction.

Future Outlook

NA

Industry Context

This filing is a routine insider transaction report and does not contain information related to broader industry trends or competitive landscape. It reflects an individual executive's equity management.

Stakeholder Impact

• Shareholders: The transaction represents a change in the direct ownership stake of a key executive. While the sale was pre-planned, some investors may monitor insider selling activity.

Next Steps

• No specific future actions or milestones for the company are mentioned in this insider transaction report.

Key Dates

Recommendation

The filing details a routine insider transaction (exercise of options and sale of shares) executed under a pre-arranged 10b5-1 plan. This type of transaction is typically for personal financial planning and does not reflect a change in the company's fundamental prospects or management's view of future performance. Therefore, it provides no new information to alter an existing investment thesis, warranting a 'hold' recommendation.

Keywords

United Therapeutics, UTHR, Form 4, insider transaction, stock options, 10b5-1 plan, equity sale, Paul A. Mahon, executive compensation